11:03 AM EDT, 06/11/2024 (MT Newswires) -- NLS Pharmaceutics ( NLSP ) said Tuesday that a new patent application for dual non-sulfonamide orexin receptor agonists by Aexon Labs has been published by the World Intellectual Property Organization.

The company said it will use the patent under its license agreement with Aexon Labs.

The dual agonists target narcolepsy, a sleep disorder, as the primary indication, and neurodegenerative conditions such as Parkinson's disease as secondary indications, said Eric Konofal, chief scientific officer of NLS Pharmaceutics ( NLSP ) and president of Aexon Labs.

Shares of NLS Pharmaceutics ( NLSP ) were up 1.8% in recent trading.